Vancouver, British Columbia | January 20, 2026 — BioVaxys Technology Corp. reported positive Phase 1B/2 clinical results from its PESCO trial, evaluating the cancer vaccine MVP-S in combination with pembrolizumab (Keytruda™) and low-dose cyclophosphamide in patients with recurrent epithelial ovarian cancer (EOC). The study demonstrated meaningful clinical activity, including a durable complete response lasting three years in one patient, and outcomes that exceeded expectations in platinum-resistant disease, a setting with historically limited treatment success.

Science Significance

From a scientific standpoint, the PESCO trial reinforces the biological rationale for combining cancer vaccines with immune checkpoint inhibition. MVP-S targets survivin, a tumor-associated antigen highly expressed in ovarian cancer but largely absent in normal tissues, enabling selective immune-mediated tumor destruction. The study reported an overall response rate (ORR) of 24% and a disease control rate (DCR) of 82%, with platinum-sensitive patients achieving an ORR of 40% and DCR of 90%. Notably, even platinum-resistant patients, who typically respond poorly to chemotherapy, achieved an ORR of 16%, surpassing historical benchmarks. The observation that 62% of evaluated patients developed survivin-specific immune responses, strongly correlated with disease control, highlights the mechanistic validity of the DPX™ immune-educating platform.

Regulatory Significance

Regulatorily, the trial met its primary objectives of safety, tolerability, and dose determination, critical milestones under Good Clinical Practice (GCP) standards. The absence of unexpected safety signals and the demonstration of sustained immune responses provide a robust foundation for advancing MVP-S into later-stage clinical development. As a Phase 1B/2 investigator-initiated study, these data will inform regulatory interactions, protocol refinements, and potential pathway discussions for future trials in platinum-resistant ovarian cancer, a population recognized by regulators as having a high unmet medical need.

Business Significance

For BioVaxys, these results represent a significant value inflection point for its oncology pipeline. Demonstrating durable clinical benefit and favorable tolerability strengthens the company’s competitive positioning in the crowded immuno-oncology landscape. The data also validate the broader applicability of the DPX™ platform, supporting its use across multiple cancer indications and combination strategies. From an industry perspective, the findings enhance partnering, licensing, and investment attractiveness, particularly as pharmaceutical companies increasingly seek differentiated immunotherapy combinations with evidence of durability rather than short-lived responses.

Patients’ Significance

For patients with recurrent EOC, the implications are substantial. Ovarian cancer is often diagnosed late and characterized by repeated relapse and drug resistance, leaving limited therapeutic options. The PESCO trial suggests that MVP-S–based combination therapy could offer clinically meaningful disease control, including long-term remission in select patients, with manageable toxicity. The possibility of achieving durable responses without the cumulative toxicity associated with repeated chemotherapy cycles represents a potential quality-of-life improvement for patients facing otherwise poor prognoses.

Policy Significance

At the policy level, these findings support ongoing efforts to encourage innovation in immunotherapy combinations and cancer vaccine development. The trial aligns with broader health policy objectives to promote precision oncology, immune-based treatments, and accelerated development for high-unmet-need cancers. As regulators and policymakers evaluate frameworks for adaptive trial designs and combination regimens, real-world data such as those from the PESCO study contribute to shaping evidence-based regulatory and reimbursement discussions.

Overall, BioVaxys’ Phase 1B/2 PESCO trial provides compelling clinical, immunological, and safety evidence supporting MVP-S as a promising component of combination immunotherapy for recurrent epithelial ovarian cancer. With durable responses, encouraging activity in platinum-resistant disease, and a clear regulatory development pathway, the results underscore the growing relevance of vaccine-based immuno-oncology strategies within the cGxP-governed clinical research landscape and set the stage for next-phase clinical advancement.

Source:  BioVaxys Technology press release